[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628883":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX",null,"Follow-up as part of the usual care of patients with mid\u002Flower rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX induction chemotherapy.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Stéphane BENOIST, MD PhD","CONTACT","+33 (0)1 45 21 34 72","stephane.benoist@aphp.fr",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Solafah ABDALLA, MD PhD","+33 (0)1 45 21 34 70","solafah.abdalla@aphp.fr",[23],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Digestive Surgery Department, Bicêtre University Hospital AP-HP","RECRUITING","Le Kremlin-Bicêtre","94270","France","FR",{"type":31,"coordinates":32},"Point",[33,34],2.36073,48.81471,{"lat":34,"lon":33},[37,38,39],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},{"name":14,"role":40,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100628883","folfirinox-induction-chemotherapy-for-synchronous-liver-metastases-100628883",false,"NCT07467434","FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases","Multicenter Cohort Study of Mid\u002FLower Rectal Cancer With Resectable Synchronous Liver Metastases Treated With FOLFIRINOX Induction Chemotherapy","SYNCHRONOX","Inclusion Criteria:\n\n* Adult subjects aged 18 years and older\n* Adenocarcinoma of the middle and\u002For lower rectum pMMR T3, T4, and\u002For N+\n* Resectable synchronous liver metastases\n\nExclusion Criteria:\n\n* Minor under the age of 18.\n* Presence of extrahepatic metastases\n* Induction chemotherapy with FOLFIRINOX of less than 2 courses","ALL","18 Years",{"count":54,"type":55},550,"ESTIMATED","OBSERVATIONAL","SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and\u002For N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.",[59,60,61,62],"Rectal Cancer","Synchronous Liver Metastases","Antineoplastic Combined Chemotherapy Protocols","Surgical Therapy",[64,65],"Prospective observational multicentric cohort","Retrospective observational multicentric cohort","2026-06-05",{"date":68,"type":69},"2026-06-09","ACTUAL",{"date":71,"type":69},"2026-05-01",{"date":73,"type":55},"2034-05-01",{"name":5,"class":6},1]